Edivaldo dos Santos Rodrigues

I graduated in Natural Science with qualification in chemistry by the State University of Pará (2021), and at prensent I am a Ph.D student at the Walter Mors Institute of Natural Product, Health Sciences Center of the Federal University of Rio de Janeiro, Brazil. My field of research is that of computational chemistry directed mostly to medicinal chemistry, structure biology, and reaction mechanism modeling of organic and enzyme catalysis reactions.

EDUCATION

Graduated in Natural Science with qualification in chemistry by the State University of Pará (2021).

RESEARCH, TEACHING, or OTHER INTERESTS

Physical and Theoretical Chemistry, Structural Biology, Biochemistry, Organic Chemistry

Scopus Publications

Asymmetric transfer hydrogenation of polyoxygenated 3-arylidenechroman-4-ones: a powerful tool for the total synthesis of natural homoisoflavonoids
Juliane S. Falcão, Marcos V. O. da Silva, Edivaldo S. Rodrigues, Osvaldo A. Santos-Filho, Paulo R. R. Costa, Guilherme S. Caleffi
Organic Chemistry Frontiers, 2026
A mild and highly efficient one-pot asymmetric transfer hydrogenation (ATH) of challenging, electron-rich 3-arylidenechroman-4-ones is reported.
Ruthenium Complexes Containing Thiobenzamide Act as Potent and Selective Anti-Trypanosoma cruzi Agents through Apoptotic Cell Death
Maria Vitória Gomes das Neves, Isabela Santos Cezar, Edivaldo dos Santos Rodrigues, Felipe Cardoso Teixeira Bomfim, Ricardo da Silva Duarte, Claudia Valeria Campos de Souza, Vinícius Pinto Costa Rocha, Denise Santos de Sá, Osvaldo Andrade Santos-Filho, Carlos Daniel Silva da Silva, Milena Botelho Pereira Soares, Cássio Santana Meira
ACS Infectious Diseases, 2026
.
The Alkaloid Caulerpin Exhibits Potent and Selective Anti-Inflammatory Activity Through Interaction with the Glucocorticoid Receptor
Jônatas Sousa Pires dos Santos, Dahara Keyse Carvalho Silva, Vanessa da Silva Oliveira, Sergio Santos Silva Junior, Edivaldo dos Santos Rodrigues, Claudia Valeria Campos de Souza, Sabrina Teixeira Martinez, Osvaldo Andrade Santos-Filho, Cássio Santana Meira, Milena Botelho Pereira Soares
Marine Drugs, 2025
Inflammation plays a central role in various pathological conditions, necessitating the search for safer and more effective anti-inflammatory agents. This study investigates the anti-inflammatory activity of caulerpin, a bisindolic alkaloid isolated from Caulerpa racemosa. In vitro assays demonstrated that caulerpin significantly reduced nitric oxide, TNF-α, IL-6, and IL-12 levels in macrophages stimulated with LPS + IFN-γ, without affecting cell viability. In silico toxicity predictions using Protox 3.0 reinforce a favorable safety profile of caulerpin. Molecular docking and molecular dynamics simulations revealed its high-affinity binding to the glucocorticoid receptor ligand-binding domain (GR-LBD), suggesting a mechanism of action similar to dexamethasone. The involvement of the glucocorticoid receptor was confirmed by the partial reversal of caulerpin’s effects upon RU486 treatment. In vivo, caulerpin exhibited a favorable safety profile, with no signs of acute toxicity at an oral dose of 100 mg/kg. Moreover, in a mouse model of endotoxic shock, caulerpin administration significantly improved survival rates in a dose-dependent manner, providing complete protection at 4 mg/kg. These findings highlight caulerpin as a promising candidate for the development of novel anti-inflammatory therapies. Further studies are warranted to explore its pharmacokinetics, optimize its structure, and evaluate its efficacy in chronic inflammatory diseases.
In silico, in vitro, and in vivo assessment of anti-Trypanosoma cruzi activity of the 1H-indazole-containing ruthenium complex FOR0E2
Isabela Santos Cezar, Maria Vitória Gomes das Neves, Jaqueline Wang da Silva, Ivanilson Pimenta Santos, Danilo Kleber Santos Sales, Edivaldo dos Santos Rodrigues, Claudia Valeria Campos de Souza, Gabriela Cruz Fernandes, Carlos Daniel Silva da Silva, Denise Santos de Sá, Osvaldo Andrade Santos-Filho, Milena Botelho Pereira Soares, Cássio Santana Meira
Acta Tropica, 2025
Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19
Michela Murdocca, Osvaldo Andrade Santos-Filho, Claudia De Masi, Edivaldo dos Santos Rodrigues, Claudia Valeria Campos de Souza, Riccardo De Santis, Donatella Amatore, Andrea Latini, Rossella Schipani, Lino di Rienzo Businco, Bruno Brandimarte, Giorgia Grilli, Tien L Huang, Annie S Mayence, Florigio Lista, Andrea Duranti, Federica Sangiuolo, Jean Jacques Vanden Eynde, Giuseppe Novelli
Biology Direct, 2024
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is reliably one of the largest pandemics the world has suffered in recent years. In the search for non-biological antivirals, special emphasis was placed on drug repurposing to accelerate the clinical implementation of effective drugs.The life cycle of the virus has been extensively investigated and many human targets have been identified, such as the molecular chaperone GRP78, representing a host auxiliary factor for SARS-CoV-2 entry. Here we report the inhibitor capacity of TL1228, a small molecule discovered through an in silico screening approach, which could interfere with the interaction of SARS-CoV-2 and its target cells, blocking the recognition of the GRP78 cellular receptor by the viral Spike protein. TL1228 showed in vitro the ability to reduce significantly both pseudoviral and authentic viral activity even through the reduction of GRP78/ACE2 transcript levels. Importantly, TL1228 acts in modulating expression levels of innate immunity and as inflammation markers.
Solidagenone from Solidago chilensis Meyen Protects against Acute Peritonitis and Lipopolysaccharide-Induced Shock by Regulating NF-κB Signaling Pathway
Ivanilson Pimenta Santos, Laís Peres Silva, Dahara Keyse Carvalho Silva, Bruna Padilha Zurita Claro dos Reis, Temistocles Barroso de Oliveira, Andressa Maia Kelly, Edivaldo dos Santos Rodrigues, Claudia Valeria Campos de Souza, José Fernando Oliveira-Costa, Simone Sacramento Valverde, Osvaldo Andrade Santos-Filho, Milena Botelho Pereira Soares, Cássio Santana Meira
Pharmaceuticals, 2024
Anti-inflammatory agents are widely used for the treatment of inflammatory diseases. Nevertheless, the associated side effects of the available drugs make it necessary to search for new anti-inflammatory drugs. Here, we investigated the anti-inflammatory activity of solidagenone. Initially, we observed that a single dose of 30, 60, or 90 mg/kg of solidagenone did not result in mortality or elicit any discernible signs of toxicity in mice. At the same doses, solidagenone promoted a significant reduction in the migration of neutrophils in an acute peritonitis model and decreased mortality in a lipopolysaccharide-induced endotoxic shock model. Interestingly, treatment with solidagenone conferred a protective effect against leukopenia and thrombocytopenia, hematological disorders commonly observed in sepsis conditions. In addition, treatment with all the doses of solidagenone promoted a significant reduction in nitric oxide, TNF-α, and IL-1β levels relative to the LPS-stimulated vehicle-treated cultures. Furthermore, gene expression and in silico analyses also supported the modulation of the NF-κB pathway by solidagenone. Finally, in silico pharmacokinetics predictions indicated a favorable drugability profile for solidagenone. Taken together, the findings of the present investigation show that solidagenone exhibits significant anti-inflammatory properties in acute experimental models, potentially through the modulation of the NF-κB signaling pathway.